Ara-C, Idarubicine and Gentuzumab Ozogamicin (AIM) as Salvage Treatment in Advanced Acute Myeloid Leukemia Patients.

MLA

Capria, Saveria, et al. “Ara-C, Idarubicine and Gentuzumab Ozogamicin (AIM) as Salvage Treatment in Advanced Acute Myeloid Leukemia Patients.” Mediterranean Journal of Hematology and Infectious Diseases, vol. 4, no. 1, 2012, p. e2012072. EBSCOhost, https://doi.org/10.4084/MJHID.2012.072.

APA

Capria, S., Trisolini, S. M., Minotti, C., Stefanizzi, C., Cardarelli, L., Cartoni, C., Diverio, D., De Propris, M. S., Mancini, M., Micozzi, A., Foà, R., & Meloni, G. (2012). Ara-C, Idarubicine and Gentuzumab Ozogamicin (AIM) as Salvage Treatment in Advanced Acute Myeloid Leukemia Patients. Mediterranean Journal of Hematology and Infectious Diseases, 4(1), e2012072. https://doi.org/10.4084/MJHID.2012.072

Chicago

Capria, Saveria, Silvia Maria Trisolini, Clara Minotti, Caterina Stefanizzi, Luisa Cardarelli, Claudio Cartoni, Daniela Diverio, et al. 2012. “Ara-C, Idarubicine and Gentuzumab Ozogamicin (AIM) as Salvage Treatment in Advanced Acute Myeloid Leukemia Patients.” Mediterranean Journal of Hematology and Infectious Diseases 4 (1): e2012072. doi:10.4084/MJHID.2012.072.